Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Collection

IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients

Bone Marrow Transplantation volume 40, pages 1019–1025 (2007)Cite this article

Abstract

We explored the efficacy of the IGEV regimen (ifosfamide, gemcitabine, vinorelbine and prednisone) combined with a fixed dose of lenograstim (263 μg/day) to mobilize peripheral blood stem cells (PBSCs) in 90 Hodgkin's lymphoma patients. The median total CD34+ cells/μl peak, colony-forming units granulocyte–macrophage and white blood cells for all individual collection sets were 85/μl, 12 × 104/kg and 20 700/μl, respectively. An adequate number of CD34+ cells (more than 3 × 106 or 6 × 106 CD34+ cells/kg depending on whether single or tandem high-dose chemotherapy was used) were collected in 89 out of 90 (98.7%) mobilized patients, whereas the only failure reached 2.3 × 106 CD34+ cells/kg. The median CD34+ cell collections were 11 × 106/kg (range 2.3–39 × 106/kg) and 10 × 106/kg (range 6–22.0 × 106/kg) with a median of 1 and 2 leukaphereses for patients eligible for single high-dose treatment and for candidates for tandem transplant, respectively. Target yields were reached in 71.43 and 49.09% and additionally in 17.14 and 43.64% of cases after the first and second apheresis procedures, respectively. Hematological and non-hematological side effects were acceptable, and no toxic deaths occurred. Thirty-four patients received a single and 47 received tandem transplantation with rapid engraftment. These results confirm that the IGEV regimen with lenograstim support can be used successfully and safely to mobilize PBSCs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054.

    Article  CAS  Google Scholar 

  2. Magagnoli M, Castagna L, Balzarotti M, Demarco M, Santoro A . What is the best option to cure patients with resistant/relapse Hodgkin's disease? Curr Stem Cell Res Ther 2006; 1: 419–424.

    Article  CAS  Google Scholar 

  3. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. German Hodgkin's lymphoma Study group; lymphoma working party of the European group for blood and marrow transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  Google Scholar 

  4. Seyfarth B, Josting A, Dreyling M, Schmitz N . Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol 2006; 133: 3–18.

    Article  Google Scholar 

  5. Alexandrescu DT, Karri S, Wiernick PH, Duthcher JP . Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma 2006; 47: 641–656.

    Article  CAS  Google Scholar 

  6. Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003; 14: 1762–1767.

    Article  CAS  Google Scholar 

  7. Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 1998; 103: 533–535.

    Article  CAS  Google Scholar 

  8. Ferme C, Bastion Y, Lepage E, Berger F, Brice P, Morel P et al. MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995; 6: 543–549.

    Article  CAS  Google Scholar 

  9. Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G et al. Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma. Leuk Lymphoma 2004; 45: 2079–2084.

    Article  CAS  Google Scholar 

  10. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 1628–1635.

    Article  CAS  Google Scholar 

  11. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M . Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106: 353–360.

    Article  CAS  Google Scholar 

  12. Martin A, Fernandez-Jimenez MC, Caballero MD, Canales MA, Perez-Simon JA, Garcia de Bustos J et al. Long-term follow-up in patients treated with mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001; 113: 161–171.

    Article  CAS  Google Scholar 

  13. McQuaker I, Haynes A, Stainer C, Byrne J, Russell N . Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant 1999; 24: 715–722.

    Article  CAS  Google Scholar 

  14. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J . Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645–652.

    Article  Google Scholar 

  15. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G et al. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 688–697.

    Article  CAS  Google Scholar 

  16. Ribrag V, Nasr F, Bouhris JH, Bosq J, Brault P, Girinsky T et al. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refarctory Hodgkin's disease. Bone Marrow Transplant 1998; 21: 969–974.

    Article  CAS  Google Scholar 

  17. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999; 11: 3632–3636.

    Google Scholar 

  18. Bartlett N, Niedzwiecki D, Johnson J, Friedberg J, Johnson K, van Besien K et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071–1079.

    Article  CAS  Google Scholar 

  19. Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B et al. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma 2005; 46: 1017–1022.

    Article  CAS  Google Scholar 

  20. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M et al. Ifosfamide, gemcitabine, and vinorelbine (IGEV): a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92: 35–41.

    Article  CAS  Google Scholar 

  21. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. Am J Haematol 2007; 82: 122–127.

    Article  CAS  Google Scholar 

  22. Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P et al. Vinorelbine: an active drug in the management of patients with heavily pre-treated Hodgkin's disease. Ann Oncol 1994; 5: 817–820.

    Article  CAS  Google Scholar 

  23. La Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C et al. High-dose ifosfamide: circumvention of resistance to standard dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600–1608.

    Article  Google Scholar 

  24. Magagnoli M, Sarina B, Balzarotti M, Castagna L, Timofeeva I, Nozza A et al. Mobilising potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001; 28: 923–927.

    Article  CAS  Google Scholar 

  25. Lucas JB, Horwitz SM, Horning SJ, Sayegh A . Gemcitabine is active in relapsed Hodgkin's disease. J Clin Oncol 1999; 17: 2627–2628.

    Article  CAS  Google Scholar 

  26. Zinzani PL, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85: 926–929.

    CAS  PubMed  Google Scholar 

  27. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615–2625.

    Article  CAS  Google Scholar 

  28. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I . ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 2006; 37: 277–282.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy

    M Magagnoli, M Balzarotti, I Timofeeva, R Capizzuto, E Morenghi, L Castagna & A Santoro

  2. Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy

    M Spina, M Michieli & U Tirelli

  3. Division of Internal Medicine, San Luigi Hospital, Gorgonzola, Italy

    L Isa

Authors
  1. M Magagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Spina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Balzarotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Timofeeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Isa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Michieli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Capizzuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Morenghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. U Tirelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Magagnoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magagnoli, M., Spina, M., Balzarotti, M. et al. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant 40, 1019–1025 (2007). https://doi.org/10.1038/sj.bmt.1705862

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705862

Keywords

This article is cited by

Search

Advanced search

Quick links